Prospective observational study of breast cancer treatment outcomes for UK women aged 18-40 years at diagnosis: The POSH study

Journal of the National Cancer Institute

Volumn 105, Issue 13, 2013, Pages 978-988

  Copson, Ellen ^a   Eccles, Bryony ^a   Maishman, Tom ^a   Gerty, Sue ^a   Stanton, Louise ^a   Cutress, Ramsey I ^a   Altman, Douglas G ^b   Durcan, Lorraine ^a   Simmonds, Peter ^a   Lawrence, Gill ^c   Jones, Louise ^d   Bliss, Judith ^e   Eccles, Diana ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GAMMA UROGASTRONE; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; COHORT ANALYSIS; DISEASE FREE INTERVAL; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGE FACTORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; GREAT BRITAIN; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPH NODES; LYMPHATIC METASTASIS; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; TAMOXIFEN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84880193768     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt134     Document Type: Article

References (40)

1. Cancer Research UK. http://info.cancerresearchuk.org/cancerstats/types/ breast/incidence. Accessed June 2012.
2. Adami HO, Malker B, Holmberg L, et al. The relation between survival and age at diagnosis in breast cancer. N Engl J Med.1986;315(9):559-563.
3. Albain KS, Allred DC, Clark GM. Breast cancer outcome and predictors of outcome: are there age differentials? J Natl Cancer Inst Monogr. 1994;(16):35-42.
4. Fowble BL, Schultz DJ, Overmoyer B, et al. The influence of young age on outcome in early stage breast cancer. Int J Radiat Oncol Biol Phys. 1994;30 (1):23-33.
5. Nixon AJ, Neuberg D, Hayes DF, et al. Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. J Clin Oncol. 1994;12(5):888-894.
6. Chung M, Chang HR, Bland KI, et al. Younger women with breast carcinoma have a poorer prognosis than older women. Cancer. 1996;77(1):97-103.
7. Gajdos C, Tartter PI, Bleiweiss IJ, et al. Stage 0 to stage III breast cancer in young women. J Am Coll Surg. 2000;190(5):523-529.
8. Ahn SH, Son BH, Kim SW, et al. Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea-a report from the Korean Breast Cancer Society. J Clin Oncol. 2007;25(17):2360-2368.
9. Fredholm H, Eaker S, Frisell J, et al. Breast cancer in young women: poor survival despite intensive treatment. PLoS One. 2009;4(11):e7695.
10. Gnerlich JL, Deshpande AD, Jeffe DB, et al. Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early-stage disease. J Am Coll Surg. 2009;208(3):341-347.
11. Xiong Q, Valero V, Kau V, et al. Female patients with breast carcinoma age 30 years and younger have a poor prognosis: the M.D. Anderson Cancer Center experience. Cancer. 2001;92(10):2523-2528.
12. El Saghir NS, Seoud M, Khalil MK, et al. Effects of young age at presentation on survival in breast cancer. BMC Cancer. 2006;6:194.
13. Winchester D P, Osteen RT, Menck HR. The National Cancer Data Base report on breast carcinoma characteristics and outcome in relation to age. Cancer. 1996;78(8):1838-1843.
14. Colleoni M, Rotmensz N, Robertson C, et al. Very young women (<35 years) with operable breast cancer: features of disease at presentation. Ann Oncol. 2002;13(2):273-279.
15. Kheirelseid EH, Boggs JM, Curran C, et al. Younger age as a prognostic indicator in breast cancer: a cohort study. BMC Cancer. 2011;11:383.
16. Liukkonen S, Leidenius M, Saarto T, et al. Breast cancer in very young women. Eur J Surg Oncol. 2011;37(12):1030-1037.
17. Gonzalez-Angulo AM, Broglio K, Kau SW, et al. Women age < or = 35 years with primary breast carcinoma: disease features at presentation. Cancer. 2005; 103(12):2466-2472.
18. Anders CK, Hsu DS, Broadwater G, et al. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol. 2008;26(20):3324-3330.
19. Goldhirsch A, Glick JH, Gelber RD, et al. International Consensus Panel on the treatment of primary breast cancer. V: Update 1998. Recent Results Cancer Res.1998;152:481-497.
20. Bonnier P, Romain S, Charpin C, et al. Age as a prognostic factor in breast cancer: relationship to pathologic and biologic features. Int J Cancer. 1995; 62(2):138-144.
21. Livi L, Meattini I, Saieva C, et al. The impact of young age on breast cancer outcome. Eur J Surg Oncol. 2010;36:639-645.
22. Wishart GC, Azzato EM, Greenberg DC, et al. PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer. Breast Cancer Res. 2010;12(1):401.
23. Lalloo F, Varley J, Moran A, et al. BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives. Eur J Cancer. 2006; 42(8):1143-1150.
24. Ginsburg OM, Akbari MR, Aziz Z, et al. The prevalence of germ-line TP53 mutations in women diagnosed with breast cancer before age 30. Fam Cancer. 2009;8(4):563-567.
25. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453-1457.
26. Eccles D, Gerty S, Simmonds P, et al. Prospective study of Outcomes in Sporadic versus Hereditary breast cancer (POSH): study protocol. BMC Cancer. 2007;7:160.
27. Azzato EM, Greenberg D, Shah M, et al. Prevalent cases in observational studies of cancer survival: do they bias hazard ratio estimates? Br J Cancer. 2009;100(11):1806-1811.
28. Lambert PC, Royston P. Further development of flexible parametric models for survival analysis. Stata J. 2009;9:265-290.
29. Evans DG, Howell A, Ward D, et al. Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer. J Med Genet. 2011;48(8):520-522.
30. Anderson WF, Chen BE, Jatoi I, et al. Effects of estrogen receptor expression and histopathology on annual hazard rates of death from breast cancer. Breast Cancer Res Treat. 2006;100(1):121-126.
31. Yu K, Wu J, Shen Z, Shao Z. Hazard of breast cancer-specific mortality among women with oestrogen-receptor positive breast cancer after five years from diagnosis: implication for extended endocrine therapy. J Clin Endocrin Metab. 2012;97:E2201-2209.
32. Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamox-ifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst. 1996;88(21):1529-1542.
33. Goss P, Ingle J, Martino S. Outcomes of women who were premenopausal at diagnosis of early stage breast cancer in the NCIC CTG MA17 trial. Cancer Res. 2009;69(suppl 24):abstract 13.
34. Davies C, Pan H, Gray R, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of the oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381(9869):805-816.
35. Pritchard KI. Adjuvant therapy of the very young woman. Breast. 2007;16(suppl 2):S136-146.
36. National Institute for Health and Clinical Excellence. Early and locally advanced breast cancer; diagnosis and treatment. NICE Clinical Guideline 80, 2009. http://guidance.nice.org.uk/CG80/Guidance/pdf/English. Accessed June 2012.
37. Kroman N, Jensen MB, Wohlfahrt J, et al. Factors influencing the effect of age on prognosis in breast cancer: population based study. BMJ. 2000;320(7233):474-478.
38. Peto R, Davies C, Godwin J, et al. Comparisons between different poly-chemotherapy regimens for early breast cancer: meta-analyses of longterm outcome among 100, 000 women in 123 randomised trials. Lancet. 2012;379(9814):432-444.
39. National Cancer Intelligence Network. The second all breast cancer report. 2011. http://www.ncin.org.uk/view.aspx?rid=612. Accessed June 2012.
40. Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer. 2007;109(9):1721-1728.